Ann: Paradigm (PAR) Updated Investor Presentation, page-16

My bet is that it will go back down to low $1's if no deal comes in the next month or two, or deal is significantly under people's expectations of $1bn+ like a lot of those paid reports have been schilling around. That's what I'm banking on. I can't see a large player which would be willing to fork out a lot of money for a repurposed drug, reasonably limited patent life on the OA indication (particularly what will be left after time taken for a Ph3 trial and approval process), and has many alternative treatment options ranging from simply losing weight and all the way up to surgery. I've already made enough off this one (bought in at high 20's and sold out at $1.80), and will be back in if the price is right, I just think (like when it ran up to $1.50 pre-result and then over $2 after the Ph2 result, a lot of fluff is being expected with a low likelihood of actually happening - brought on perhaps by some of these research notes which have been bought and paid for with company money. Anyways, rant over and of course all the above is IMHO only.